In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


G2M Cancer Drugs AG

Division of Onxeo SA

Latest From G2M Cancer Drugs AG

Pushing Ahead with IPOs in Europe

European private companies and VCs are faring no better than their US counterparts when it comes to IPOs so far in 2005. But a series of bad haircuts and poor aftermarket performances hasn't scared everybody off, yet.
BioPharmaceutical Europe

Emergings in Brief (2/02)

Start-Up showcases the following recently launched companies: CardioSense Ltd., G2M Cancer Drugs AG, Genome Explorations Inc. and Proacta Therapeutics Ltd.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Onxeo SA
  • Senior Management
  • Bernd Hentsch, PhD, CEO
  • Contact Info
  • G2M Cancer Drugs AG
    Phone: (49) 69 63 395 164
    Paul Ehrlich Str. 42-44
    Frankfurt am Main, 60596